ArticleInternational journal of ophthalmology2026
Modular surgical approach for angle-closure glaucoma secondary to nanophthalmos.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore and summarize outcomes of a modular surgical approach for the personalized management of angle-closure glaucoma (ACG) secondary to nanophthalmos.
methodsThis was a retrospective interventional case series involving consecutive patients with nanophthalmos and ACG. All patients were treated with a modular surgical approach tailored to their specific disease characteristics, which included the following surgical combinations: Procedure I [phacoemulsification (phaco)+goniosynechialysis (GSL)], Procedure II [Procedure I +irido-zonulo-hyaloid-vitrectomy (IZHV)], Procedure III [phaco+IZHV+Ahmed glaucoma valve (AGV) implantation], and Procedure IV (Procedure III+scleral window creation).
resultsA total of 92 eyes from 62 patients were enrolled, with a median age of 52 (range: 23-72)y and a median axial length of 19.89 (range: 14.84-20.99) mm. According to the patients' distinct clinical characteristics, 14, 26, 22, and 30 eyes underwent Procedures I, II, III, and IV, respectively. The median follow-up duration was 13 (range: 12-36)mo. At the final follow-up visit, all patients achieved a sustained intraocular pressure (IOP) below 21 mm Hg without the administration of anti-glaucoma medications. Postoperative complications included malignant glaucoma (MG, 9 eyes), uveal effusion (UE, 5 eyes), suprachoroidal hemorrhage (1 eye), fibrin membrane formation (4 eyes), uveitis (1 eye), macular edema (1 eye), and impaired corrected distance visual acuity (CDVA, 6 eyes). Univariate analysis revealed that younger age was associated with a higher risk of MG (OR: 1.06,
conclusionThe modular surgical approach yields favorable and consistent clinical prognoses, while reducing the incidence of complications, in the challenging clinical scenario of ACG secondary to nanophthalmos.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.